Tempo Therapeutics Reports the First Patient Dosing in the MOSAIC Trial of TT101 for Tissue Repair in Skin Cancer Surgery
Shots:
- Tempo Therapeutics has dosed the first patient in the MOSAIC Trial of TT101, developed using MAP technology, for tissue regeneration
- The MOSAIC trial is assessing the safety of TT101 for use on surgical sites in the skin after basal cell and squamous cell carcinoma resection. TT101 and MAP technology aim to improve healing in complex surgical sites, addressing a major unmet need, especially for immunocompromised patients
- TT101 has shown non-immunogenic & regenerative tissue responses across soft tissue repair studies in animals, leading its advancement to human trials
Ref: Tempo Therapeutics | Image: Tempo Therapeutics
Related News:- Sun Pharma Entered into a License Agreement with Philogen to Commercialize Nidlegy for Skin Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
